8-K: Helius Medical Launches $92.8M ATM Stock Offering

Helius Medical Technologies, Inc. has entered into a new sales agreement to offer and sell up to $92.8 million of its Class A common stock through an at-the-market offering.

Summary

• Helius Medical Technologies, Inc. (the Company) entered into a Sales Agreement with Clear Street LLC and Maxim Group LLC as co-sales agents on September 15, 2025.
• The Company may offer and sell shares of its Class A common stock from time to time, having an aggregate sales price of up to $92.8 million, through an "at-the-market" (ATM) offering.
• The previous sales agreement, dated June 23, 2023, between the Company and Roth Capital Partners, LLC, was terminated prior to the execution of the new Sales Agreement.
• The Agents will receive commissions of up to 3.00% of the aggregate gross proceeds from each sale of shares.
• The Company has agreed to reimburse certain legal expenses incurred by the Agents, up to $75,000, in addition to certain ongoing legal expenses.
• At a special meeting of stockholders held on May 23, 2025, the Company's stockholders approved an increase in the number of authorized shares of Common Stock to up to 800,000,000 shares.
• The Company intends to file an amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to reflect the increased authorized shares.
• The Company has detailed representations and warranties regarding its Crypto Assets, including ownership, custody arrangements with Anchorage, and management by Pantera Capital Management LP, ensuring compliance with applicable laws and internal controls.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure future capital through a flexible ATM offering, which is generally positive for liquidity. However, it also signals potential future dilution for existing shareholders and introduces an unusual element with the detailed disclosure of crypto asset management, which could be viewed with mixed sentiment depending on investor perspective.

Positives

• Secures a flexible capital raising mechanism (ATM offering) for future funding needs, allowing the company to raise capital opportunistically based on market conditions.
• Increased authorized shares provide sufficient capacity for the ATM offering and future equity issuances, demonstrating proactive corporate planning.
• The new Sales Agreement with Clear Street LLC and Maxim Group LLC replaces a previous agreement, potentially optimizing terms or agent relationships.

Negatives

• Potential for dilution for existing shareholders due to the issuance of new common stock under the ATM offering.
• The "at-the-market" nature means the price and amount of shares sold are uncertain, potentially leading to sales at lower prices depending on market conditions.
• Costs associated with the offering include up to 3.00% commissions to agents and up to $75,000 in initial legal expenses, plus ongoing legal expenses, which will reduce net proceeds.

Risks

• No assurance can be given that the Company will sell any shares under the Sales Agreement, or, if it does, as to the price or the amount of shares that it sells or the dates when such sales will take place.
• The Company or the Agents may suspend or terminate the offering upon notice, which could impact the Company's ability to raise capital when needed.
• The Company's ability to sell shares is subject to compliance with Form S-3 eligibility and transaction requirements, including maintaining a public float of $75 million or more.
• Risks associated with the company's ownership, custody, transfer, and management of Crypto Assets, including compliance with various regulatory bodies (SEC, CFTC, FinCEN, OFAC, state regulators).
• Reliance on third-party custodians (Anchorage) and asset managers (Pantera Capital Management LP) for Crypto Assets introduces counterparty and operational risks.

Future Outlook

The company intends to file an amendment to its certificate of incorporation to increase the number of authorized shares of Common Stock to 800,000,000. The Sales Agreement provides a flexible mechanism for future capital raises, though there is no obligation to sell any shares, and the timing and pricing are subject to market conditions.

Management Comments

• The Company intends to file an amendment to the Companys certificate of incorporation with the Secretary of State of the State of Delaware to increase the number of shares of Common Stock authorized to 800,000,000 shares.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly those in growth-oriented sectors like medical technology, allowing them to tap into equity markets as needed without the upfront costs and market disruption of a traditional underwritten offering. The explicit mention of Crypto Assets and related management/custody arrangements is unusual for a medical technology company and could indicate diversification or treasury management strategies that deviate from typical industry practices.

Comparison to Industry Standards

• The 3.00% commission rate for an ATM offering is within the typical range for such agreements, which often fall between 1% and 3.5% depending on company size, liquidity, and market conditions.
• The increase in authorized shares is a standard corporate action to facilitate future equity issuances, including ATM offerings, and is common among companies seeking growth capital.
• The disclosure of Crypto Asset holdings and management arrangements is not a standard practice for medical technology companies and warrants further investigation into the company's treasury management or strategic diversification. Comparable companies in the medical technology sector typically do not disclose such holdings as a core part of their financial operations.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the issuance of new shares. Provides the company with access to capital, which could support growth initiatives or operational needs.
• Company: Enhanced financial flexibility and liquidity through the ATM offering. Incurs costs related to agent commissions and legal expenses.

Next Steps

• The company may issue placement notices to the agents to sell shares under the Sales Agreement.
• The company intends to file an amendment to its certificate of incorporation to increase authorized common stock to 800,000,000 shares.
• The agents will use commercially reasonable efforts to sell Placement Shares consistent with normal trading practices.

Key Dates

Recommendation

The ATM offering provides Helius Medical Technologies with a flexible mechanism to raise capital, which is a positive for its long-term financial stability and ability to fund operations or growth initiatives. However, the potential for significant shareholder dilution from the issuance of up to $92.8 million in new stock, combined with the unusual and detailed disclosure of crypto asset management for a medical technology company, introduces elements of uncertainty and risk. While the capital access is beneficial, the dilution and the non-core crypto asset strategy warrant a cautious 'hold' stance until further clarity on the use of proceeds and the impact of these strategies on core business performance is available.

Keywords

Helius Medical Technologies, HSDT, ATM Offering, At-the-Market, Equity Offering, Common Stock, Capital Raise, SEC Filing, Form 8-K, Dilution, Clear Street LLC, Maxim Group LLC, Authorized Shares, Corporate Governance, Crypto Assets, Digital Assets, Anchorage, Pantera Capital Management LP